Not yet recruiting NCT05172284
Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Questionnaires.
- Who it may be relevant to
- Registry conditions: ImmuNe-Mediated Inflammatory Diseases. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases (IMIDs) REMIND Study
Overview
Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies. This aim is achieved by evaluating the achievement of PASI 50 and PASI 75 scores at week 16 from the start of treatment.
Interventions
- Other Questionnaires
This is a collection of data from normal clinical routine: patients will be asked to record the assessments they undergo during their course of treatment, without changing clinical practice in any way. Data inherent to the following procedures will be collected: examinations, laboratory tests, imaging tests, questionnaires and rating scales.
Primary outcome measures
- Registry of ImmuNe-mediated inflammatory Diseases (IMIDs) [Time frame: 15 years]
Secondary outcome measures (2)
- PASI 50 [Time frame: 15 years]
- PASI 75 [Time frame: 15 years]
Eligibility criteria
Inclusion criteria
- Patients with a diagnosis of IMID.
- Patients of any age, including minors.
- Patients treated with approved medications for the condition in question and/or phototherapy.
- Patients who agree to sign informed consent.
Exclusion criteria
- Patients without a diagnosis of IMID.
- Patients who do not consent to sign informed consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Italy · 1 center
- IRCCS Istituto Ortopedico Galeazzi — Milan
Identifiers
NCT: NCT05172284 · REMIND